Here, we studied the effects of TLR activation and the pharmacological inhibition of IRAK4 with ND2158, an IRAK4 competitive inhibitor, as a therapeutic approach in CLL. The gene discussed is IRAK4; the disease is B-cell chronic lymphocytic leukemia.